Immunohistochemical analysis provided key discriminatory evidence: the pancreatic tumor showed diffuse positivity for CK7, CK19, and DPC4 (SMAD4), and was entirely negative for the breast-specific markers GATA3 and GCDFP-15 (9, 10). This evidence concerns the gene SMAD4 and pancreatic neoplasm.